Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZVRA 
Zevra Therapeutics Inc. (ZVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ZVRA (4-star) is a STRONG-BUY. BUY since 8 days. Simulated Profits (1.50%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.22
1 Year Target Price $23.22
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.33% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 606.54M USD | Price to earnings Ratio - | 1Y Target Price 23.22 |
Price to earnings Ratio - | 1Y Target Price 23.22 | ||
Volume (30-day avg) 7 | Beta 1.5 | 52 Weeks Range 6.19 - 13.16 | Updated Date 10/19/2025 |
52 Weeks Range 6.19 - 13.16 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.26% | Operating Margin (TTM) -47.64% |
Management Effectiveness
Return on Assets (TTM) -18.85% | Return on Equity (TTM) 3.53% |
Valuation
Trailing PE - | Forward PE 11.78 | Enterprise Value 382282697 | Price to Sales(TTM) 9.78 |
Enterprise Value 382282697 | Price to Sales(TTM) 9.78 | ||
Enterprise Value to Revenue 6.16 | Enterprise Value to EBITDA 10.49 | Shares Outstanding 56135091 | Shares Floating 46855960 |
Shares Outstanding 56135091 | Shares Floating 46855960 | ||
Percent Insiders 0.78 | Percent Institutions 65.04 |
Upturn AI SWOT
Zevra Therapeutics Inc.
Company Overview
History and Background
Zevra Therapeutics, formerly KemPharm, refocused its strategy in 2023 to focus on rare diseases. Its roots include development of prodrugs. The current strategy includes in-licensing and development of rare disease therapies. KemPharm was founded in 2006.
Core Business Areas
- Rare Disease Therapeutics: Development and commercialization of therapies for rare diseases. Focus areas include therapies for sleep disorders and rare neurological conditions.
Leadership and Structure
Neil F. McFarlane serves as the President and CEO. The company has a typical corporate structure with departments for research, development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- OLPUDICu2122 (dimesylate) Oral Solution: OLPUDIC is used to treat acute pain in adults. Revenue from this product is ramping up post launch (2024). Competitors include generic opioids and NSAIDs.
- Arimoclomol: Arimoclomol is under development to treat Niemann-Pick disease Type C (NPC). It has orphan drug designation. Competitors depend on the market approval of the drug, currently no direct competition.
Market Dynamics
Industry Overview
The rare disease therapeutics market is experiencing substantial growth, driven by increased awareness, regulatory incentives (e.g., orphan drug designation), and technological advancements in diagnostics and drug development.
Positioning
Zevra is positioning itself as a key player in the rare disease space through in-licensing and development of novel therapies. Competitive advantages include focusing on unmet medical needs and leveraging regulatory pathways to accelerate drug approval.
Total Addressable Market (TAM)
The global rare disease therapeutics market is projected to reach hundreds of billions of dollars. Zevra's positioning is tied to securing significant market share in niche areas with high unmet needs.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases with high unmet needs
- Experienced management team
- Orphan drug designation for Arimoclomol provides market exclusivity
- OLPUDIC is on the market now and generating revenue
Weaknesses
- Reliance on regulatory approvals for product pipeline
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on in-licensing for product development
Opportunities
- Expanding product portfolio through strategic acquisitions and partnerships
- Leveraging government incentives for rare disease drug development
- Entering new geographic markets
- Potential for breakthrough therapies in underserved rare disease populations.
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies
- Generic entry eroding market share.
Competitors and Market Share
Key Competitors
- RLYP
- FOLD
- RARE
Competitive Landscape
Zevra is a smaller player compared to established pharmaceutical giants. Its advantage lies in focusing on niche rare disease markets with limited competition, however, they need to continue innovating to be competitive.
Major Acquisitions
OLPUDIC (dimesylate)
- Year: 2024
- Acquisition Price (USD millions): 15
- Strategic Rationale: Acquisition of OLPUDIC provides a revenue-generating product, which allows Zevra to expand into a product ready for commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to strategic shifts and acquisitions. KemPharm had a different focus previously, with Zevra growing in 2023 after that shift.
Future Projections: Future growth is tied to regulatory approval of Arimoclomol and the successful commercialization of new products. Analyst estimates vary based on pipeline success.
Recent Initiatives: Recent initiatives include acquiring OLPUDIC, and focusing on the Niemann-Pick Type C.
Summary
Zevra Therapeutics is a small company focused on rare disease markets and is reliant on pipeline progress. OLPUDIC provides revenue and is a step into commercialized product. The company is small and needs to continue to manage its financial and operational risks. The company faces threats from clinical trial failures and potential regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zevra Therapeutics Inc.
Exchange NASDAQ | Headquaters Celebration, FL, United States | ||
IPO Launch date 2015-04-16 | President, CEO & Director Mr. Neil F. McFarlane | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://zevra.com |
Full time employees 59 | Website https://zevra.com | ||
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.